{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093346","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2026-08-10T20:04:20+00:00","discovered_at":"2026-08-10T20:05:01.445787+00:00","generated_at":"2026-08-10T20:05:12.799795+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tactile Medical Q2 revenue up 9% to $85.7M, EPS $0.34, FY26 guidance narrowed","bullets":["Q2 2026 revenue $85.7M, +9% YoY; net income $7.8M vs $3.2M; diluted EPS $0.34 vs $0.14","Adjusted EBITDA $11.4M vs $7.7M; gross margin 76% vs 75%; lymphedema +12%, airway clearance -7%","Six-month revenue $161.0M +15% YoY; net income $6.0M vs $0.2M; adjusted EBITDA $15.1M vs $7.4M","FY2026 revenue guidance narrowed to $360-366M (from $360-368M); adjusted EBITDA maintained at $49-51M","Exclusive U.S. VA/DoD distribution deal for ElastiMed's MyoSleeve; launched next-gen AffloVest; $5.3M share repurchase"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093346","json":"https://secwatch.observer/filing/0001104659-26-093346.json","markdown":"https://secwatch.observer/filing/0001104659-26-093346.md","text":"https://secwatch.observer/filing/0001104659-26-093346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000110465926093346/0001104659-26-093346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000110465926093346/tcmd-20260810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:05:12.799795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}